GlassScriptPhysician profile
Michael G Hilman
NPI 1740277375
$6,829.01
in general payments reported to CMS, 2019-2025
26 companies · $82.93 in 2025
The $82.93 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,765 · 2020: $683 · 2021: $1,094 · 2022: $1,174 · 2023: $1,201 · 2024: $829 · 2025: $82.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,460.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $972.12 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $594.17 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.51 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $518.03 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $452.28 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $357.85 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $325.68 | 2021-2024 | |
| Amgen INC. | $293.95 | 2019-2024 | Otezla, Repatha, Prolia |
| Abbott Laboratories | $248.58 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Novo Nordisk INC | $198.88 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $195.52 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $134.89 | 2024-2025 | Voquezna |
| Genentech USA, INC. | $120.70 | 2019-2021 | |
| Sanofi Pasteur INC. | $109.56 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $73.54 | 2019 | |
| Shire North American Group INC | $55.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.22 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $17.89 | 2021 | |
| Exact Sciences Corporation | $15.59 | 2024 | Cologuard Collection Kit |
| Nabriva Therapeutics, Plc | $15.49 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.15 | 2022 | |
| Circassia INC. | $13.60 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.43 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $12.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hilman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.